NEW YORK (TheStreet) -- CHANGE IN RATINGS
downgraded at Baird from Outperform to Neutral. $16 price target. Survey suggests that marketing spending could slow down.
downgraded at UBS from Buy to Neutral. $30 price target. Health care reform costs could delay the ongoing margin expansion.
upgraded at Morgan Joseph from Hold to Buy. $66 price target. Company is seeing better sales of Revlimid.
upgraded at Deutsche to Buy. LTL pricing appears to have reached an inflection point.
downgraded at Goldman from Buy to Neutral. Recent data suggests that television demand could fall in China and North America.
downgraded at Wells to Market Perform. Company should benefit from share repurchases, but lacks other visible catalysts.
upgraded at BMO from Market Perform to Outperform. Valuation call, based on a $48 price target.
downgraded at BofA/Merrill to Underperform from Neutral on slowdown in various consumer end markets. Maintain $18 price target.
More on Microsoft The Microsoft Kinect Problem
upgraded at Janney from Neutral to Buy. $30 price target. Windows and Office product cycles are performing well.
New Jersey Resources Corp
initiated at BofA/Merrill with a Neutral rating and $37 price target. Earnings stability priced in.
added to Conviction Sell List at Goldman Sachs. Industry should see lower sales in the coming quarters.
price target lower at Barclays to $33 from $42 on near-term FX impact and higher spending. Maintain Overweight rating.
rated new Neutral at Susquehanna Financial. Company has exposure to a U.S. drilling recovery, but earnings power could be limited.
upgraded at UBS from Neutral to Buy. $55 price target. Estimates also boosted, given favorable pricing and mobile design wins.
rated new Market Perform at Rodman. Short-term growth has slowed along with the macro environment.
downgraded at BofA/Merrill to Neutral from Buy. Incremental weakness in Europe and a global near term peak in automotive SAAR is likely to drive estimates lower. Maintain $27 price target.
downgraded at Baird from Outperform to Neutral. $35 price target. Weaker consumer environment could hurt second-half results.
upgraded at UBS from Neutral to Buy. $47 price target. Valuation call, as wood product prices have found support.
STOCK COMMENTS / EPS CHANGES
target lowered at Janney Montgomery to $35. Company lacks catalysts after CS5. Buy rating.
price target lower at BofA/Merrill to $37 from $41 on concerns about the speed of Xiaflex launch. Maintain Buy rating.
( EP) estimates lowered at Morgan Stanley through 2012. Company updated guidance, regarding the Ruby land grant. Overweight rating and $15 price target.
numbers cut at Goldman. Shares of GE now seen reaching $18. Estimates also reduced, given lower industrial expectations, as well as pension and currency costs. Buy rating.
cut from Conviction Buy List at Goldman. Current quarter could mark the peak in growth for the industrial business. $46 price target.
upgraded at Janney from Neutral to Buy. $40 price target. Company is seeing better orders and margins should improve.
target, estimates cut at Credit Suisse. K price target reduced to $61 from $63. 2010 and 2011 EPS estimates trimmed to $3.55 and $3.92, respectively. Would be buyers of the stock on weakness. Maintain Outperform rating.
target raised at RBC. Shares of KLAC now seen reaching $37. Company is likely seeing strong orders and will likely host an upbeat analyst meeting.
added to Conviction Buy List at Goldman. Domestic cigarette business is improving. $96 price target.
estimates increased at Goldman through 2012. Company should benefit from higher Toy Story 3 box office results. Neutral rating.
target reduced at UBS to $10. Financing environment remains challenging. Neutral rating.
added to Conviction Buy List at Goldman. Company should benefit from continued smartphone growth, especially with Android. $43 price target.
This article was written by a staff member of TheStreet.